Last $18.96 USD
Change Today -0.16 / -0.84%
Volume 277.3K
ZFGN On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZFGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $21.96
52 Week Low
08/4/14 - $17.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZAFGEN INC (ZFGN)

Related News

No related news articles were found.

zafgen inc (ZFGN) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZFGN) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

13 Employees
Last Reported Date: 08/14/14
Founded in 2005

zafgen inc (ZFGN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $520.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Compensation as of Fiscal Year 2013.

zafgen inc (ZFGN) Key Developments

Frances K. Heller Rejoins Zafgen, Inc. as Board of Director and Member of Audit Committee

Zafgen, Inc. announced that Frances K. Heller will rejoin company's Board of Directors and will also be a member of the Audit Committee. Ms. Heller previously served as a company director from October 2011 to December 2013, and left the Board as she joined Bristol-Myers Squibb to lead its business development group. Most recently, she was senior vice president of business development at Bristol-Myers Squibb and a Trustee of the Bristol Myers Foundation. In addition, she currently serves as a Trustee of the Dana Farber Cancer Institute.

Zafgen, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter Ended June 30, 2014

Zafgen, Inc. announced unaudited consolidated financial results for the second quarter ended June 30, 2014. For the quarter, the company reported loss from operations of $5.986 million against $2.975 million a year ago. Net loss attributable to common stockholders was $6.443 million or $2.96 per diluted share against $3.190 million or $4.37 per diluted share a year ago.

Zafgen, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 11:00 AM

Zafgen, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 11:00 AM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZFGN:US $18.96 USD -0.16

ZFGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZFGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZFGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at